In this episode of the Illusion of Consensus podcast, Dr. Matt Johnson and I discuss the recent FDA decision regarding MDMA therapy for PTSD. The conversation covers the FDA's commitment to transparency in drug approval processes, the specific concerns raised in the rejection of MDMA therapy, and the implications for future psychedelic treatments. Dr. Johnson emphasizes the need for a fair evaluation process and the potential benefits of MDMA therapy compared to traditional SSRIs, while also addressing the importance of understanding the durability of treatment effects and the biases present in clinical trials. Chapters 00:00 Introduction to Psychedelic Research and FDA Transparency 02:39 FDA's Rejection of MDMA Therapy: Key Concerns 04:55 Exploring the FDA's Feedback on MDMA Therapy 12:18 Durability of MDMA's Effects in PTSD Treatment 16:59 Comparing MDMA Therapy to SSRIs for PTSD 20:51 Effect Sizes and Future of Psychedelic Treatments 28:38 MDMA Use and Treatment Efficacy 32:02 Pre-Screening and Selection Bias in Trials 34:38 Durability of Treatment Effects 36:32 Long-Term Efficacy and Safety of SSRIs 39:29 Societal Factors in Mental Health Treatment 42:43 The Role of Psychedelics in Therapy 46:50 Future of Psychedelic Therapy and FDA Regulations This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe
